1.
Hood L, Balling R, Auffray C. Revolutionizing medicine in the 21st century through systems approaches. Biotechnol J 2012;7:992–1001.Web of ScienceGoogle Scholar
2.
Flores M, Glusman G, Brogaard K, Price ND, Hood L. P4 medicine: how systems medicine will transform the healthcare sector and society. Per Med 2013;10:565–76.Google Scholar
3.
Xu S, Zhang Y, Jia L, Mathewson KE, Jang K-I, Kim J, et al. Soft microfluidic assemblies of sensors, circuits, and radios for the skin. Science 2014;344:70–4.Web of ScienceGoogle Scholar
4.
Gibbs WW. Medicine gets up close and personal. Nature 2014;506:144–5.Web of ScienceGoogle Scholar
5.
Hood L, Lovejoy JC, Price ND. Integrating big data and actionable health coaching to optimize wellness. BMC Med 2015;13:4.CrossrefWeb of ScienceGoogle Scholar
6.
Kaiser J. Google X sets out to define healthy human. Science insider 2014. Available from: http://scim.ag/googlehuman.
7.
Diamandis EP. The hundred person wellness project and Google’s baseline study: medical revolution or unnecessary and potentially harmful over-testing? BMC Med 2015;13:5.CrossrefWeb of ScienceGoogle Scholar
8.
Wilcken B. Newborn screening: gaps in the evidence. Science 2013;342:197–8.Web of ScienceGoogle Scholar
9.
Wilson MG, Jungner G. Principles and practice for screening for disease. Public Health Papers 34; Geneva: World Health Organization, 1968.Google Scholar
10.
Welch HG. Overdiagnosis and mammography screening. Br Med J 2009;339:182–3.Web of ScienceGoogle Scholar
11.
Skeggs LT Jr. Persistence…and prayer. From the artificial kidney to the autoanalyzer. Clin Chem 2000;46:1425–36.Google Scholar
12.
Anonymous. Bargain genome. Nature 2014;505:458–9.Google Scholar
13.
Chrystoja CC, Diamandis EP. Whole genome sequencing as a diagnostic test: challenges and opportunities. Clin Chem 2014;60:1–10.Web of ScienceGoogle Scholar
14.
Yang Y, Muzay DM, Reid JG, Bainbridge MN, Willis A, Ward PA, et al. Clinical whole-exome sequencing for the diagnosis of mendelian disorders. N Engl J Med 2013;369:1502–11.Web of ScienceGoogle Scholar
15.
Esplin ED, Oei L, Snyder MP. Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease. Pharmacogenomics 2014;15:1771–90.CrossrefWeb of ScienceGoogle Scholar
16.
Van Allen EM, Wagle N, Stojanov P, Perrin DL, Cibulskis K, Marlow S, et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med 2014;20:682–8.Web of ScienceCrossrefGoogle Scholar
17.
Garralda E, Paz K, López-Casas PP, Jones S, Katz A, Kann LM, et al. Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment. Clin Cancer Res 2014;20:2476–84.Web of ScienceGoogle Scholar
18.
Ellis MJ. Mutational analysis of breast cancer: guiding personalized treatments. Breast 2013;22:S19–21.CrossrefGoogle Scholar
19.
Anonymous. The FDA and me. Nature 2013;504:7–8.Google Scholar
20.
Annas GD, Sherman E. 23andMe and the FDA. N Engl J Med 2014;370:985–8.Google Scholar
21.
Church G. Genomics is mired in misunderstanding. Nature 2013;502:143.Google Scholar
22.
Roberts NJ, Vogelstein JT, Parmigiani G, Kinzler KW, Vogelstein B, Valculescu VE. The predictive capacity of personal genome sequencing. Sci Transl Med 2012;4:133ra58.CrossrefWeb of ScienceGoogle Scholar
23.
Castle PE. Teaching moment: why promising biomarkers do not always translate into clinically useful tests. J Clin Oncol 2014;32:359–61.Web of ScienceGoogle Scholar
24.
Esserman LJ, Thompson IM Jr, Reid B. Overdiagnosis and overtreatment of cancer. An opportunity for improvement. J Am Med Assoc 2013;310:397–8.Google Scholar
25.
Schiffman M, Solomon D. Cervical – cancer screening with human papillomavirus and cytologic cotesting. N Engl J Med 2013;369:2324–31.Web of ScienceGoogle Scholar
26.
Levin TR, Corley DA. Colorectal – cancer screening – coming of age. N Engl J Med 2013;396:1164–6.Google Scholar
27.
Kistler CE. Colorectal – cancer incidence and mortality after screening. N Engl J Med 2013;396:2354–5.Google Scholar
28.
Bleyer A, Welch HG. Effect of three decades of screening mammography on breast – cancer incidence. N Engl J Med 2012;367:1998–2005.Web of ScienceGoogle Scholar
29.
Biller-Andorno N, Juni P. Abolishing mammography screening programs. A view from the Swiss Medical Board. N Eng J Med 2014;370:1965–7.Google Scholar
30.
Aberle DR, DeMello S, Berg CD, Black WC, Brewer B, Church TR, et al. Results of the two incidence screenings in the national lunch screening trial. N Engl J Med 2013;369:920–31.Google Scholar
31.
Maldonado F, Peikert T, Midthun D. Cancer in pulmonary nodules detected on first screening CT. N Engl J Med 2013;396:2060–1.Web of ScienceGoogle Scholar
32.
McWilliams A, Tammemagi MC, Mayo JR, Roberts H, Liu G, Soghrati K, et al. Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med 2013:369:910–9.Web of ScienceGoogle Scholar
33.
Moyer VA. Screening for lung cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 2014;160:330–8.Web of ScienceGoogle Scholar
34.
Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK collaborative trial of ovarian cancer screening (UKCTOCS). Lancet Oncol 2009;10:327–40.CrossrefWeb of ScienceGoogle Scholar
35.
Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009:360:1310–9. Erratum in: N Engl J Med 2009;360:1797.Google Scholar
36.
Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320–8.Web of ScienceGoogle Scholar
37.
Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366:981–90. Erratum in: N Engl J Med 2012;366:2137.Google Scholar
38.
Wade J, Rosario DJ, Macefield RC, Avery KN, Salter CE, Goodwin ML, et al. Physchological impact of prostate biopsy: physical symptoms, anxiety, and depression. J Clin Oncol 2013;31:4235–41.Google Scholar
39.
Basch E, Oliver TK, Vickers A, Thompson I, Kantoff P, Parnes H, et al. Screening for prostate cancer with prostate-specific antigen testing: American society of clinical oncology provisional clinical opinion. J Clin Oncol 2012;30:3020–5.Web of ScienceGoogle Scholar
40.
Thompson IM, Tangen CM. Prostate cancer – uncertainty and a way forward. N Engl J Med 2012;376:270–1.Web of ScienceGoogle Scholar
41.
Hayes JH, Barry MJ. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. J Am Med Assoc 2014;311:1143–9.Web of ScienceGoogle Scholar
42.
Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367:203–13.Web of ScienceGoogle Scholar
43.
Froehner M, Writh MP. Early prostate cancer – treat or watch? N Engl J Med 2011;365:568–9.Google Scholar
44.
Solomon BD. Incidentalomas in genomics and radiology. N Engl J Med 2014;370:988–90.Google Scholar
45.
MacArthur DG, Manolio TA, Dimmock DP, Rehm HL, Shendure J, Abecasis GR, et al. Guidelines for investigating causality of sequence variants in human disease. Nature 2014;508:469–76.Web of ScienceGoogle Scholar
46.
Fisher B, Redmond C, Poisson R, Margolese R, Wolmark N, Wickerham L, et al. Eight-year results of randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1989;320:822–8.Google Scholar
47.
Anonymous. Prostate cancer: send away the PSA? Lancet 2012;380:307.Google Scholar
Comments (0)